Clinical trial
Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With…
NCT00011895 · GlaxoSmithKline, Industry · Unknown status
Key facts
| NCT number | NCT00011895 |
|---|---|
| Title | Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs |
| Official title | A Phase IV Multicenter Study of the Efficacy and Safety of 48-Week Induction Treatment With TRIZIVIR (Abacavir 300 Mg/Lamivudine 150 Mg/Zidovudine 300 Mg Combination Tablet BID) With Efavirenz (600 Mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment With TRIZIVIR With or Without… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz |
| Enrollment | 400 |
| Start date | Feb 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: